Key Points:
- AI-designed drugs could enter clinical trials by the end of 2025: Alphabet’s subsidiary, Isomorphic Labs, is on track to test its first AI-generated therapeutics for major diseases.
- Generative AI enables breakthroughs in drug discovery: AI models like AlphaFold are revolutionizing the identification of novel molecules and drug targets.
- Global interest in AI-driven medicine is growing: Startups and researchers worldwide are leveraging AI to address public health challenges, such as creating new antibiotics and treating rare diseases.
As reported by Quartz, the use of generative artificial intelligence (AI) in drug discovery is poised to transform how diseases are treated. At the forefront of this innovation is Alphabet’s drug discovery subsidiary, Isomorphic Labs, which aims to revolutionize medicine through AI-driven breakthroughs. According to Demis Hassabis, CEO of Google DeepMind and founder of Isomorphic Labs, the company is focusing on developing treatments for “all the big disease areas,” including oncology, cardiovascular conditions, and neurodegenerative disorders.
“We’ll hopefully have some AI-designed drugs in the clinic by the end of the year. That’s the plan,” Hassabis announced during a panel at the World Economic Forum in Davos, Switzerland. He emphasized that the application of AI to science extends far beyond language models, highlighting the transformative potential of technologies like AlphaFold, an AI system that predicts a protein’s 3D structure.
Founded in 2021 as a stand-alone subsidiary under Alphabet, Isomorphic Labs has partnered with pharmaceutical giants such as Eli Lilly and Novartis. These collaborations aim to leverage AI to discover therapeutics targeting multiple diseases. Hassabis reiterated that by year’s end, the company anticipates its first AI-designed drug entering clinical trials.
A Growing Trend in AI-Driven Medicine
Isomorphic Labs is not alone in its pursuit of AI-driven drug discovery. The field has witnessed a surge of interest, with startups and researchers worldwide embracing generative AI to address pressing healthcare needs. For instance, Stanford University’s Professor James Zou has used AI to design novel molecules, noting the untapped potential of synthetic compounds as effective drugs.
“Our hypothesis was that there are a lot of potential molecules out there that could be effective drugs, but we haven’t made or tested them yet,” said Zou. He emphasized the urgency of developing new antibiotics, a critical public health priority.
One notable success story is Insilico Medicine, a Hong Kong-based startup that became the first company to send an AI-designed drug to clinical trials in 2023. The drug, INS018_055, targets idiopathic pulmonary fibrosis, a disease with no current cure that causes lung scarring. Initial trials yielded promising results. Earlier this year, Insilico reported positive topline results for AI-designed drugs aimed at treating inflammatory bowel disease and identifying potential treatments for endometriosis.
A Future Shaped by AI
The integration of AI into drug discovery holds immense promise. By accelerating the identification of novel molecules and streamlining the development process, AI has the potential to address unmet medical needs and tackle a wide range of diseases. As Isomorphic Labs and other innovators push the boundaries of what’s possible, the future of medicine may soon be transformed by breakthroughs designed by artificial intelligence.
